Anthony M. Rossi, MD
Dr. Rossi is a Fellow in Procedural Dermatology and Mohs Surgery, Memorial Sloan-Kettering and Weill Cornell/New York-Presbyterian Hospital, both in New York, New York.
Dr. Rossi reports no conflicts of interest in relation to this post.
The September 2012 issue of Dermatologic Surgery (2012;38:1497-1505) featured a randomized double-blind study to compare the safety, efficacy, and dose-response relationship of 2 doses of onabotulinumtoxinA for the treatment of hyperdynamic perioral rhytides. Sixty female participants were randomized in a 1:1 ratio to receive either 7.5 or 12.0 U of onabotulinumtoxinA at 4 perioral sites. Participants were then assessed at weeks 2, 4, 8, 12, 16, and 20. The severity of the perioral lines and participant satisfaction were assessed at all visits. [More]